These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 22579251)

  • 1. Crystal structures of a stabilized β1-adrenoceptor bound to the biased agonists bucindolol and carvedilol.
    Warne T; Edwards PC; Leslie AG; Tate CG
    Structure; 2012 May; 20(5):841-9. PubMed ID: 22579251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes.
    Asano K; Zisman LS; Yoshikawa T; Headley V; Bristow MR; Port JD
    J Cardiovasc Pharmacol; 2001 Jun; 37(6):678-91. PubMed ID: 11392464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium.
    Maack C; Cremers B; Flesch M; Höper A; Südkamp M; Böhm M
    Br J Pharmacol; 2000 Jul; 130(5):1131-9. PubMed ID: 10882399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model.
    Feuerstein G; Liu GL; Yue TL; Cheng HY; Hieble JP; Arch JR; Ruffolo RR; Ma XL
    Eur J Pharmacol; 1998 Jun; 351(3):341-50. PubMed ID: 9721026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of a beta1-adrenergic G-protein-coupled receptor.
    Warne T; Serrano-Vega MJ; Baker JG; Moukhametzianov R; Edwards PC; Henderson R; Leslie AG; Tate CG; Schertler GF
    Nature; 2008 Jul; 454(7203):486-91. PubMed ID: 18594507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of bucindolol and carvedilol on noradenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats.
    Pönicke K; Heinroth-Hoffmann I; Brodde OE
    J Pharmacol Exp Ther; 2002 Apr; 301(1):71-6. PubMed ID: 11907159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agonist actions of "beta-blockers" provide evidence for two agonist activation sites or conformations of the human beta1-adrenoceptor.
    Baker JG; Hall IP; Hill SJ
    Mol Pharmacol; 2003 Jun; 63(6):1312-21. PubMed ID: 12761341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium.
    Brixius K; Bundkirchen A; Bölck B; Mehlhorn U; Schwinger RH
    Br J Pharmacol; 2001 Aug; 133(8):1330-8. PubMed ID: 11498519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart.
    Willette RN; Mitchell MP; Ohlstein EH; Lukas MA; Ruffolo RR
    Pharmacology; 1998 Jan; 56(1):30-6. PubMed ID: 9467185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutively active mutants of the beta1-adrenergic receptor.
    Lattion A; Abuin L; Nenniger-Tosato M; Cotecchia S
    FEBS Lett; 1999 Sep; 457(3):302-6. PubMed ID: 10471797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of a carbamoyl glucuronide conjugate of carvedilol in vitro using dog and rat liver microsomes.
    Schaefer WH
    Drug Metab Dispos; 1992; 20(1):130-3. PubMed ID: 1346989
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiac adrenergic receptor effects of carvedilol.
    Yoshikawa T; Port JD; Asano K; Chidiak P; Bouvier M; Dutcher D; Roden RL; Minobe W; Tremmel KD; Bristow MR
    Eur Heart J; 1996 Apr; 17 Suppl B():8-16. PubMed ID: 8733065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Markedly reduced effects of (-)-isoprenaline but not of (-)-CGP12177 and unchanged affinity of beta-blockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors.
    Joseph SS; Lynham JA; Grace AA; Colledge WH; Kaumann AJ
    Br J Pharmacol; 2004 May; 142(1):51-6. PubMed ID: 15037517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gα
    Wang J; Hanada K; Staus DP; Makara MA; Dahal GR; Chen Q; Ahles A; Engelhardt S; Rockman HA
    Nat Commun; 2017 Nov; 8(1):1706. PubMed ID: 29167435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structural basis for agonist and partial agonist action on a β(1)-adrenergic receptor.
    Warne T; Moukhametzianov R; Baker JG; Nehmé R; Edwards PC; Leslie AG; Schertler GF; Tate CG
    Nature; 2011 Jan; 469(7329):241-4. PubMed ID: 21228877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perturbing effects of carvedilol on a model membrane system: role of lipophilicity and chemical structure.
    Butler S; Wang R; Wunder SL; Cheng HY; Randall CS
    Biophys Chem; 2006 Feb; 119(3):307-15. PubMed ID: 16243429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Partial agonist activity of bucindolol is dependent on the activation state of the human beta1-adrenergic receptor.
    Maack C; Böhm M; Vlaskin L; Dabew E; Lorenz K; Schäfers HJ; Lohse MJ; Engelhardt S
    Circulation; 2003 Jul; 108(3):348-53. PubMed ID: 12847069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereoselective glucuronidation of carvedilol in human liver and intestinal microsomes.
    Hanioka N; Tanaka S; Moriguchi Y; Narimatsu S
    Pharmacology; 2012; 90(3-4):117-24. PubMed ID: 22814440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of the CYP1A subfamily in stereoselective metabolism of carvedilol in beta-naphthoflavone-treated Caco-2 cells.
    Ishida K; Taguchi M; Akao T; Hashimoto Y
    Biol Pharm Bull; 2009 Mar; 32(3):513-6. PubMed ID: 19252307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carvedilol, a beta adrenoceptor blocker with chelating properties. A copper 'superdimer' based on dimetal units.
    Zoroddu MA; Grepioni F; Franconi F
    J Inorg Biochem; 2003 Jul; 95(4):315-20. PubMed ID: 12818802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.